drugset / Trial / NCT02420587

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT02420587 ↗

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is learn how AMG208 may help to control prostate cancer that has spread to the bone. The safety of the drug will also be studied.

Timeline

Start
2014-10
Primary completion
2019-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 208 Small molecule 400 mg Oral

Indications